Biosimilars and the long game

Farah Huzair, Dinar Kale

Research output: Contribution to journalArticlepeer-review


Despite greater certainty for biosimilar markets and regulation, the change that was seen in the small-molecule pharmaceuticals market with the rapid entrance of emerging-country generics suppliers will not be replicated exactly. The long game has yet to be played out, and recent changes in regulation, science, and production technology are likely to impact on future patterns of partnership and production.
Original languageEnglish
Pages (from-to)250-252
JournalTrends in biotechnology
Issue number5
Early online date20 Apr 2015
Publication statusPublished - May 2015


  • biosimilar
  • follow-on biologic
  • subsequent entry biologic


Dive into the research topics of 'Biosimilars and the long game'. Together they form a unique fingerprint.

Cite this